Genomic copy number alterations in clear cell renal carcinoma: Associations with case characteristics and mechanisms of VHL gene inactivation

Oncogenesis

Volumn 1, Issue 6, 2012, Pages

  Moore, L E ^a   Jaeger, E ^b   Nickerson, M L ^c   Brennan, P ^d   De Vries, S ^b   Roy, R ^b   Toro, J ^a   Li, H ^e   Karami, S ^a   Lenz, P ^f   Zaridze, D ^g   Janout, V ^h   Bencko, V ⁱ   Navratilova, M ^j   Szeszenia Dabrowska, N ^k   Mates, D ^l   Linehan, W M ^a   Merino, M ^a   Simko, J ^b   Pfeiffer, R ^a   Boffetta, P ^m,n   Hewitt, S ^a   Rothman, N ^a   Chow, W H ^a   Waldman, F M ^b   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e NEW YORK UNIVERSITY   (United States)

^f SAIC FREDERICK INC   (United States)

^g N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^h PALACKÝ UNIVERSITY   (Czech Republic)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^k NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^l NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ International Cancer Prevention Research Institute   (France)

more..

Author keywords

epidemiology; renal cancer; VHL

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

AGE; ARTICLE; CANCER PATIENT; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENDER; GENE AMPLIFICATION; GENE INACTIVATION; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SMOKING; WILD TYPE;

EID: 84868284256     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.14     Document Type: Article

References (34)

1. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14: 288-301.
2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Meanue M et al. (2008) Cancer Incidence in Five Continents, vol. IX. IARC Scientific Publications, Lyon, France, 1980.
3. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170: 2163-2172. (Pubitemid 37413950)
4. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al. Identification of the von Hippel-Lindau disease tumor-suppressor gene. Science 1993; 260: 1317-1320. (Pubitemid 23231974)
5. Maxwell PH, Weisener MS, Chang GW, Clifford SC, Vaux EC, Cockman M et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999; 399: 271-275. (Pubitemid 29246458)
6. Kaelin Jr. WG. Molecular basis of the VHL heteditary cancer syndropme. Nat Rev Cancer 2002; 2: 673-682. (Pubitemid 37328918)
7. Golshayan AR, Brick AJ, Choueiri TK. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 2008; 4: 85-92. (Pubitemid 351372609)
8. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N et al. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 2009; 101: 1417-1424.
9. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94: 1569-1575. (Pubitemid 35277281)
10. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005; 13: 859-864.
11. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006; 98: 756-762. (Pubitemid 44368020)
12. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Hamden P et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009; 15: 7582-7592.
13. Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J et al. Association of somatic VHL alteration with risk factors for RCC and germline VHL gene locus polymorphisms. PLoS Genet 2011; 7: E1002312.
14. Brennan P, van der Hel O, Moore LE, Zaridze D, Matveev V, Holcatova I et al. Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br J Cancer 2008; 99: 1912-1915.
15. Hsu CC, Chow WH, Boffetta P, Moore L, Zaridze D, Moukeria A et al. Dietary risk factors for kidney cancer in Eastern and Central Europe. Am J Epidemiol 2007; 166: 62-70. (Pubitemid 47234290)
16. Moore LE, Boffetta P, Karami S, Brennan P, Stewart PS, Hung R et al. Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants. Cancer Res 2010; 70: 6527-6536.
17. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10k single nucleotide polymorphism mapping array. Neoplasia 2008; 10: 634-642. (Pubitemid 351883879)
18. Arai E, Ushijima S, Tsuda H, Fjimoto H, Hosoda F, Shibata T et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res 2008; 14: 5531-5539.
19. Beroukhim R, Brunet JP, di Napoli A, Mertz KD, Seeley A, Pires MM et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau diseaseassociated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69: 4674-4681.
20. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 2009; 125: 2342-2348.
21. Shuib S, Wei W, Sur H, Morris MR, McMullan D, Ratternberry E et al. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma. Genes Chromosomes Cancer 2011; 50: 479-488.
22. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti Jr JC et al. Arraybased comparative genomic hybridizaiont for the differential diagnosis of renal cell cancer. Cancer Res 2002; 62: 957-960. (Pubitemid 34160268)
23. Wali A. FHIT: Doubts are clear now. Sci World J 2010; 10: 1142-1151.
24. Xiao GH, Jin F, Klein-Szanto AJP, Goodrow TL, Linehan MW, Yeung RS. The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers. Am J Pathol 1997; 151: 1541-1548.
25. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3: 748-754. (Pubitemid 35446744)
26. Hodgson G, Hager GH, Volik S, Horiono S, Wernick M, Moore D et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 2001; 29: 459-464. (Pubitemid 34326698)
27. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D et al. High resloultion analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-211. (Pubitemid 28455458)
28. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004; 5: 557-572. (Pubitemid 41180205)
29. Gentleman R, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
30. Willenbrock H, Fridlyand J. A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics 2005; 21: 4084-4091. (Pubitemid 41672097)
31. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541. (Pubitemid 44854748)
32. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2004; 3Article 3.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 1995; 57: 289-300.
34. R Development Core TeamR. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2010; ISBN 900051-07-0URL http://www.R-project.org.